- Home
- CISS vs KTTA Comparison
CISS vs KTTA Comparison
Compare CISS & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | KTTA |
|---|---|---|
| Founded | 2022 | 2020 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISS | KTTA |
|---|---|---|
| Price | $0.25 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 875.3K | ★ 21.6M |
| Earning Date | 11-18-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,613,149.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.28 |
| 52 Week High | $11.52 | $3.85 |
Technical Indicators
Market Signals| Indicator | CISS | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 15.99 | 59.16 |
| Support Level | $1.76 | $1.09 |
| Resistance Level | $1.94 | $1.23 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 0.97 | 46.55 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).